Tolvaptan

托伐普坦

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NameTolvaptan
Drug Alias Name托伐坦tolvaptanum替伐普坦Jinarc苏麦卡 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin V2 receptor antagonists
TargetsVasopressin V2 receptor
Therapy Area/IndicationsEdemaFibrosisAscites +[16] 
Global Approved IndicationsHyponatremiaHeart FailurePolycystic Kidney, Autosomal Dominant +[4] 
Approved Indications in ChinaHyponatremia
Original Approved Country/TerritoryUnited States
Original Approved Date2009/05/19
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOtsuka Holdings Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesOtsuka Holdings Co LtdOtsuka Pharmaceutical Development & Commercialization IncOtsuka Pharmaceutical Co Ltd +[6] 
Inactive CompaniesThe Brigham and Women's HospitalOtsuka America Pharmaceutical IncTaiwan Otsuka Pharmaceutical Co Ltd +[7] 
Active IndicationsFibrosisHyponatremiaHeart Failure +[7] 
Inactive IndicationsEdemaAscitesWater Intoxication +[9] 

Other Information

ATC CodeC03XA01
Related LinksWikipediaDrugBankKEGG